Solving the limited availability of Astatine-211 from a European perspective: from production to the end user
With all efforts in production and making <sup>211</sup>At available it has the potential to be the next generation Targeted Alpha Therapy radionuclide in Europe and worldwide.
Authors
- Renata Mikołajczak (ORCID: https://orcid.org/0000-0002-6882-751X)
- Hanne Jensen (ORCID: https://orcid.org/0000-0002-7550-9894)
- Haingo Rabarijaona
- Hans Van de Maele
- Emma Aneheim
- Sture Lindegren
Institutions
- Sahlgrenska University Hospital (SE)
- Rigshospitalet (DK)
- Wallonie-Bruxelles International (BE)
- National Centre for Nuclear Research (PL)
- University of Gothenburg (SE)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1186/s41181-026-00428-0
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 31.92